Why Does Compressomygography (CMG) Enhanced by NMTCuff® Offers Greater Assurance in Avoiding Residual Blockade as Compared to Acceleromyography (AMG) or Electromyography (EMG)?
Did you know that NMTCuff® technology—inside equipments like the VISION DUO—uses an advanced algorithm that determines extubation readiness based on complete recovery, rather than relying solely on the traditional 0.9 TOF ratio threshold?
Unlike conventional systems, NMTCuff® can align with 0.9 TOFr-based criteria, but it goes further: it provides a more precise and reliable indication of when extubation can occur safely. By targeting a stable, fully recovered neuromuscular state, NMTCuff® helps reduce the risk of residual blockade.
A standout feature is the AUTO-PILOT mode in the VISION DUO, which leverages NMTCuff® to achieve a “100% TOFr consolidated value.” This means it doesn’t just confirm a single threshold—it ensures recovery is stable and reproducible. The system continuously monitors and identifies the optimal moment for extubation, enhancing patient safety and aligning with expert recommendations for quantitative neuromuscular monitoring.
One of the key advantages of NMTCuff®—which stimulates at the upper arm rather than the wrist (as in AMG or EMG)—is the physiological difference in muscle response. Recovery appears earlier in the upper arm than in the wrist, creating a natural “time window” of about 5 to 10 minutes. During this period, the system can confirm recovery with multiple stable TOF ratio readings—without extending surgical time.
In essence, NMTCuff® takes advantage of this physiological lead time, combining it with automated, high-precision monitoring to ensure complete reversal. This results in a safer, more efficient extubation process that can reduce both perioperative complications and associated costs.
CMG is the new NMT monitoring generation. Please do not miss the next conference in the Carolina University next Wednesday 18th at 11:15am by Dr Wade Weigel.
https://www.med.unc.edu/anesthesiology/carolina-refresher-course/
Thursday, June 19th
- 11:15 - 11:45 am: Monitoring and Antagonism of Neuromuscular Blockade:
- ASA Practice Guidelines (PS)
- Wade Weigel, MD
Friday, June 20th
- 12:00 - 1:00 pm: Workshops / Problem-Based Learning Discussion (PBLD)
- Workshop 3: Quantity vs. Quality: A Comparison of Various Neuromuscular Monitoring Devices
- Wade Weigel, MD
Euroanesthesia 2025
We're thrilled to share that our participation at the ESA trade show in Lisbon was a huge success! RGB's commitment to innovation was evident in the audience, who were able to explore our NMT Cuff technology for the measurement of muscle relaxation, designed to help avoid the effect PORK and make the work of anesthesiologists easier with our innovative mode AUTO-PILOT.
We thank everyone who visited our booth and shared their enthusiasm for our mission to enhance patient safety and improve healthcare outcomes.
VISION DUO in Carolina Refresher Course
Dr. Wade Weigel, MD
My intent is to provide a balanced and evidence-based overview of the various devices available. My interest is to educate on quantitative monitoring and support product purchase decision making for the attendees. I do not care which product they choose to buy, but I want to help them make an informed decision.
Download the schedule of the Carolina Refresher Course:
ESA 2025 - NMT Tour
The tour led by Prof. Thomas Fuchs-Buder (Nancy, France) will navigate you through the of Neuromuscular transmission monitoring. In 2023 both, the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC) independently published a practice guideline for the management of neuromuscular blockade. After a short introduction, companies Idmed,Senzime and RGB Medical will present their solutions, and you will have the opportunity to discover the latest innovations and discuss directly the experts.
